GlaxoSmithKline anticipates five new products in 2007

Share this article:
GlaxoSmithKline expects to launch five new products this year, the drugmaker told investors today as it announced its 2006 financial results. “We now have over 30 significant product opportunities in phase III development or registration, including five major new products planned for launch this year,” CEO JP Garnier said in a statement. Glaxo plans to launch Tykerb for breast cancer during the first half of 2007; Allermist/Avamys for allergic rhinitis, also during the first half the year; Coreg for heart conditions during the first quarter; and Trexima for migraine during the second half of 2007. The firm also expects to file for approval for its cervical cancer vaccine Cervarix in April.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.